3-allyl-5,6-diamino-1-butyl-1H-pyrimidine-2,4-dione | 628278-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-allyl-5,6-diamino-1-butyl-1H-pyrimidine-2,4-dione
• 英文别名: 5,6-diamino-1-butyl-3-prop-2-enylpyrimidine-2,4-dione
• CAS: 628278-99-9
• 化学式: C₁₁H₁₈N₄O₂
• 分子量: 238.29
• InChiKey: QJLFQCPBXXQLSI-UHFFFAOYSA-N

物化性质

• 沸点：
  326.8±52.0 °C(Predicted)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-allyl-5,6-diamino-1-butyl-1H-pyrimidine-2,4-dione 在 咪唑 、 sodium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 为溶剂， 生成 8-benzyl-3-butyl-1-prop-2-enyl-7H-purine-2,6-dione
  参考文献：
  名称：

  Modified 3-Alkyl-1,8-dibenzylxanthines as GTP-Competitive inhibitors of phosphoenolpyruvate carboxykinase

  摘要：

  The first non-substrate like inhibitors of human cytosolic phosphoenolpyruvate carboxykinase (PEPCK) competitive with GTP are reported. An effort to discover orally active compounds that improve glucose homeostasis in Type 2 diabetics by reversibly inhibiting PEPCK led to the discovery of 1-allyl-3-butyl-8-methylxanthine (5). We now report modifications at N-1 and C-8 that improved the in vitro activity of the initial xanthine HTS hit by 100-fold and a developing SAR for this class of inhibitor. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00722-4
• 作为产物：
  描述：

  3-Allyl-6-amino-1-butyl-5-nitroso-1H-pyrimidine-2,4-dione 在 sodium dithionite 、 Ammonium hydroxide 作用下， 以 水 为溶剂， 生成 3-allyl-5,6-diamino-1-butyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  [EN] AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY
  [FR] DERIVES DE XANTHINE A SUBSTITUTION AMIDE A ACTIVITE DE MODULATION DE LA GLUCONEOGENESE

  摘要：

  本发明是一种式（I）的1,3,8取代黄嘌呤衍生物或其药用盐，其中R1、R2和R3如规范中所定义。式（I）化合物及其药用盐或前药显示为糖异生调节剂的活性。

  公开号：

  WO2003106459A1

文献信息

• Amide substituted xanthine derivatives
  申请人：——

  公开号：US20040014766A1

  公开（公告）日：2004-01-22

  The present invention is a 1,3,8 substituted xanthine derivative of formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and R 3 are as defined in the specification. Compounds of formula I and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.

  本发明是一种具有如下结构的1,3,8取代黄嘌呤衍生物（I1）或其药学上可接受的盐，其中R1、R2和R3如规范中定义。公式I的化合物及其药学上可接受的盐或前药显示出作为糖异生调节剂的活性。
• AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1515972A1

  公开（公告）日：2005-03-23
• US7135475B2
  申请人：——

  公开号：US7135475B2

  公开（公告）日：2006-11-14
• [EN] AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY<br/>[FR] DERIVES DE XANTHINE A SUBSTITUTION AMIDE A ACTIVITE DE MODULATION DE LA GLUCONEOGENESE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003106459A1

  公开（公告）日：2003-12-24

  The present invention is a 1,3,8 substituted xanthine derivative of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (I) and pharmaceutically acceptable salts or prodrugs thereof show activity as modulators of gluconeogenesis.

  本发明是一种式（I）的1,3,8取代黄嘌呤衍生物或其药用盐，其中R1、R2和R3如规范中所定义。式（I）化合物及其药用盐或前药显示为糖异生调节剂的活性。
• Modified 3-Alkyl-1,8-dibenzylxanthines as GTP-Competitive inhibitors of phosphoenolpyruvate carboxykinase
  作者：Louise H. Foley、Ping Wang、Pete Dunten、Gwendolyn Ramsey、Mary-Lou Gubler、Stanley J. Wertheimer

  DOI：10.1016/s0960-894x(03)00722-4

  日期：2003.10

  The first non-substrate like inhibitors of human cytosolic phosphoenolpyruvate carboxykinase (PEPCK) competitive with GTP are reported. An effort to discover orally active compounds that improve glucose homeostasis in Type 2 diabetics by reversibly inhibiting PEPCK led to the discovery of 1-allyl-3-butyl-8-methylxanthine (5). We now report modifications at N-1 and C-8 that improved the in vitro activity of the initial xanthine HTS hit by 100-fold and a developing SAR for this class of inhibitor. (C) 2003 Elsevier Ltd. All rights reserved.